CAS NO: | 544417-40-5 |
包装 | 价格(元) |
10 mM * 1 mL in DMSO | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
生物活性 | Capadenoson is a selective agonist ofadenosine-A1 receptor. | ||||||||||||||||
IC50& Target | Adenosine A1 receptor[1] | ||||||||||||||||
体外研究 (In Vitro) | To further elucidate the pharmacological properties of Capadenson, GTP shift assays are performed with the standard full A1-agonist CCPA and the A1-antagonist 8-cyclopentyl-1,3-dipropylxanthine (DPCPX). CCPA shows a Kivalue of 4.2 nM in the binding assay on rat cortical brain membranes. In the presence of 1 mM GTP this Kivalue shifts to a value of 64 nM. Therefore the GTP shift for CCPA is 15. DPCPX shows a GTP shift of 1 with virtually identical Kivalues in the absence and presence of GTP. Capadenson shows a Kivalue of 24 nM in the binding assay. In the presence of 1 mM GTP this Kivalue shifts to a value of 116 nM resulting in a GTP shift of 5 for Capadenoson[1]. | ||||||||||||||||
体内研究 (In Vivo) | In the in vivo experiments, Wistar rats and SHR are pre-treated with Capadenoson at a concentration of 0.15 mg/kg for 5 days. On day 5, a stress test (physical restraint) is performed for 2 hours. The plasma concentration of Capadenoson measured 3 hours after drug intake remains constant in the 5 days prior to the restraint stress test and averaged 7.63 μg/L on day 4 and 5, respectively[1]. | ||||||||||||||||
Clinical Trial | |||||||||||||||||
分子量 | 520.03 | ||||||||||||||||
性状 | Solid | ||||||||||||||||
Formula | C25H18ClN5O2S2 | ||||||||||||||||
CAS 号 | 544417-40-5 | ||||||||||||||||
中文名称 | 卡帕诺生 | ||||||||||||||||
运输条件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
储存方式 |
| ||||||||||||||||
溶解性数据 | In Vitro: DMSO : ≥ 50 mg/mL(96.15 mM) *"≥" means soluble, but saturation unknown. 配制储备液
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百
|